RespireRx Pharmaceuticals Inc (fka RSPI)

[NeutrinoKid]

I read it in full. It’s tidy and addresses all complaints, with plausible justifications, and verifiable by contacting the correspondants.

2 major grants under review,
1. NIH for epilepsy and gabakines. $2,999,738. they will hear from them Sept 30 2025. ding ding
2. NIH for ADHD and Ampakines, $2,790,269 ding ding

Castle placement will soon conduct a Rule 506(c) offering expected end Sept 2025, up to 45 millions divided in 3 entities: 5 millions for RespireRx, 15 millions for subsidiary A, 25 millions for subsidiary B - not explicitly named, but we know them, ResolutionRx, and EndeavourRx. TBA. Ding ding ding.

Other “we’re talking” players not named, but high caliber, M&A, licensing, etc. Milestones, etc. the usual.

Those non-dilutive financings would cover the backlog payments.

At least this has amply exceeded my expectations, though they were admittedly very very very low.